Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases

Authors:
  • MQMeng Qiao
    Meng Qiao
  • FZFei Zhou
    Fei Zhou
  • LHLikun Hou
    Likun Hou
  • XLXuefei Li
    Xuefei Li
  • CZChao Zhao
    Chao Zhao
  • TJTao Jiang
    Tao Jiang
  • GGGuanghui Gao
    Guanghui Gao
  • CSChunxia Su
    Chunxia Su
  • CWChunyan Wu
    Chunyan Wu
  • SRShengxiang Ren
    Shengxiang Ren

Abstract
Background: To investigate the significance of metastatic sites and their numbers to the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 232 patients who received ICI monotherapy or ICI-based combination therapy were retrospectively identified from January 2016 to February 2019. Six metastatic sites (brain, liver, bone, adrenal gland, contralateral lung, pleura) were included to analyze their significance to ICI efficacy. To explore the association between liver metastasis (LM) and tumor T cell infiltration, 46 patients with available tumor specimens were tested for PD-L1 expression, CD8+ tumor infiltrating lymphocytes (TILs) density. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier curves. Results: More metastatic organs involved were associated with significantly worse PFS (0–1 organ: 5.7 months, 2–3 organs: 3.5 months, ≥4 organs: 2.7 months, Pvs. 29.8% vs. 18.2%, Pvs. 30.8%, P=0.088). Interestingly, ICI-based combination therapy could effectively control LM with improved intrahepatic PFS (P=0.056) and ORR (41.7% vs. 6.7%, P=0.030). Conclusions: More metastatic organs involved were associated with poorer response to ICIs. LM was a negative predictive factor for patients treated with ICI monotherapy and the combination strategy might effectively control LM.